Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Masayoshi Harigai, Tsutomu Takeuchi, Josef S Smolen, et al.
Modern Rheumatology (2019) Vol. 30, Iss. 1, pp. 36-43
Open Access | Times Cited: 50

Showing 26-50 of 50 citing articles:

The safety of baricitinib in patients with rheumatoid arthritis
Suguru Honda, Masayoshi Harigai
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 5, pp. 545-551
Closed Access | Times Cited: 23
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
Kunihiro Yamaoka, Yoshiya Tanaka, Hideto Kameda, et al.
Drug Safety (2021) Vol. 44, Iss. 6, pp. 711-722
Open Access | Times Cited: 18
Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case post-marketing surveillance study
Nami Okamoto, Tatsuya Atsumi, Michiaki Takagi, et al.
Modern Rheumatology (2024)
Closed Access | Times Cited: 2
The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis
Ennio Giulio Favalli, Marco Matucci‐Cerinic, Zoltán Szekanecz
Autoimmunity Reviews (2019) Vol. 19, Iss. 1, pp. 102421-102421
Closed Access | Times Cited: 16
Safety of baricitinib in East Asian patients with moderate‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials
Ying‐Chou Chen, Dae‐Hyun Yoo, Chang Keun Lee, et al.
International Journal of Rheumatic Diseases (2019) Vol. 23, Iss. 1, pp. 65-73
Closed Access | Times Cited: 15
Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors
Won‐Ho Choi, Soo Min Ahn, Yong‐Gil Kim, et al.
Clinical Rheumatology (2022) Vol. 41, Iss. 6, pp. 1659-1663
Closed Access | Times Cited: 9
Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
Chanyuan Wu, Qian Wang, Jian Shi, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 6, pp. 1609-1622
Open Access | Times Cited: 4
Tofacitinib for the Treatment of Refractory Progressive Vitiligo: A Retrospective Case Series
Xiukun Sun, Anqi Sheng, Aie Xu
Dermatologic Therapy (2024) Vol. 2024, pp. 1-5
Open Access | Times Cited: 1
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years
Tsutomu Takeuchi, Yoshiya Tanaka, Mitsuhiro Rokuda, et al.
Modern Rheumatology (2020) Vol. 31, Iss. 3, pp. 543-555
Open Access | Times Cited: 10
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
Norito Katoh, Yasushi Takita, Yoshitaka Isaka, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 12, pp. 2765-2779
Open Access | Times Cited: 6
Severe inflammatory tinea capitis in a child receiving baricitinib therapy for alopecia areata
S. Rotaru, M. Common, E. Mahé
Annales de Dermatologie et de Vénéréologie (2023) Vol. 150, Iss. 2, pp. 160-161
Closed Access | Times Cited: 3
Necessity to screen and treat latent tuberculosis before ruxolitinib treatment—Ruxolitinib-associated disseminated tuberculosis: A case report and literature review
Nobuyasu Hirai, Kei Kasahara, Shingo Yoshihara, et al.
IDCases (2020) Vol. 21, pp. e00892-e00892
Open Access | Times Cited: 7
Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients
Karel Pavelká, Zoltán Szekanecz, Nemanja Damjanov, et al.
Drugs in Context (2020) Vol. 9, pp. 1-15
Open Access | Times Cited: 7
Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials
Jing Wu, Zhaohua Zhu, Qinghong Yu, et al.
Expert Opinion on Investigational Drugs (2019) Vol. 28, Iss. 12, pp. 1113-1123
Closed Access | Times Cited: 6
Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study
Tsutomu Takeuchi, Maureen Rischmueller, Ricardo Blanco, et al.
Modern Rheumatology (2020) Vol. 31, Iss. 3, pp. 534-542
Open Access | Times Cited: 6
Recent advance in management of herpes simplex in Japan
Shinichi Imafuku
The Journal of Dermatology (2023) Vol. 50, Iss. 3, pp. 299-304
Open Access | Times Cited: 2
Should atopic dermatitis patients starting JAK inhibitors take prophylactic acyclovir?
Milaan Shah, Katherine G. Beuerlein, Joseph L. Jorizzo, et al.
Journal of Dermatological Treatment (2021) Vol. 32, Iss. 7, pp. 669-672
Closed Access | Times Cited: 5
Serpiginous Skin Lesions Under Baricitinib Therapy
Elena Bularca, Sara Martínez Cisneros, Pablo Villagrasa‐Boli, et al.
Infectious Diseases in Clinical Practice (2024) Vol. 32, Iss. 3
Closed Access
Treatment of Autoimmune Rheumatic Disease and the Risk of Malignancy
Ziga Vodusek, Clifton O Bingham, Christopher A. Mecoli
Current Treatment Options in Rheumatology (2024) Vol. 10, Iss. 4, pp. 61-76
Closed Access
Disseminated tinea corporis under baricitinib therapy for atopic dermatitis
Zeno Fiocco, Katrin Kerl, Lars E. French, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 4
Open Access | Times Cited: 2
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years
Naoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Modern Rheumatology (2022) Vol. 33, Iss. 1, pp. 64-72
Open Access | Times Cited: 2
Use of Janus kinase inhibitors in the treatment of immunoinflammatory rheumatic diseases: safety issues
Б. С. Белов, N. V. Muravyevа, Г. М. Тарасова, et al.
Meditsinskiy sovet = Medical Council (2021), Iss. 2, pp. 76-84
Open Access | Times Cited: 2
Sicherheit von JAK-Inhibitoren
Jan Leipe
Arthritis und Rheuma (2019) Vol. 39, Iss. 04, pp. 249-252
Closed Access
Pulmonary Tuberculosis Reactivation and CNS Involvement Following Treatment of Myelofibrosis with Ruxolitinib: Case Report and Review of the Literature of Incidence in Myeloproliferative Neoplasms
Laura S. Finn, Jessica H. Foy, Evan L. Dvorin
Archives of Hematology and Blood Diseases (2020) Vol. 3, Iss. 2, pp. 11-16
Open Access
Impact of Biologic and JAK Inhibitor Therapies on TB: How Do Biologic Therapies Affect the Presentation and Treatment Course of Pulmonary TB?
Tomoshige Matsumoto
Respiratory disease series (2022), pp. 59-71
Closed Access
Previous Page - Page 2

Scroll to top